<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738475</url>
  </required_header>
  <id_info>
    <org_study_id>TGLIA-5.002</org_study_id>
    <nct_id>NCT03738475</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COUR Pharmaceutical Development Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>COUR Pharmaceutical Development Company, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects enrolled in this study will be evaluated for immune responses and histological
      changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten
      challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled clinical trial to assess the
      safety, pharmacodynamics, efficacy, and PK, of TIMP-GLIA in subjects with well-controlled
      celiac disease (CD) following an oral gluten challenge. Subjects aged 18 to 70 years
      inclusive, with documented history of biopsy-proven confirmed CD, and on a gluten-free diet
      (GFD) for a minimum of 6 months, will be screened. Subjects who meet all inclusion and no
      exclusion criteria, and provide written informed consent, will be randomized within 45 days
      after Screening to receive 2 intravenous (IV) infusions of TIMP-GLIA, 8 mg/kg up to a maximum
      of 650 mg or placebo (normal saline) in a 1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IFN-γ spot forming units</measure>
    <time_frame>6 days</time_frame>
    <description>Change from baseline in IFN-γ spot forming units following oral gluten challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IFN-γ spot forming units</measure>
    <time_frame>6 days</time_frame>
    <description>Proportion of subjects with 3-fold increase from baseline following oral gluten challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Villus height to crypt depth ratio (Vh:Cd)</measure>
    <time_frame>29 days</time_frame>
    <description>Change from baseline in Vh:Cd following oral gluten challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Villus height to crypt depth ratio (Vh:Cd)</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of subjects with ≥ 0.4 decrease in Vh:Cd following oral gluten challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal intraepithelial lymphocytes (IELs)</measure>
    <time_frame>29 days</time_frame>
    <description>Change from baseline in number of IELs following oral gluten challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gliadin-specific T cell proliferation</measure>
    <time_frame>15 days</time_frame>
    <description>Change from baseline in gliadin-specific T cell proliferation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gliadin-specific cytokine secretion</measure>
    <time_frame>15 days</time_frame>
    <description>Change from baseline in gliadin-specific cytokine secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut-homing CD4, CD8, and γδ cells</measure>
    <time_frame>6 days</time_frame>
    <description>Change from baseline in number of gut-homing CD4, CD8, and γδ cells following oral gluten challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>35 days</time_frame>
    <description>Frequency of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>TIMP-GLIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline administered intravenously on days 1 and 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIMP-GLIA</intervention_name>
    <description>8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8</description>
    <arm_group_label>TIMP-GLIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered intravenously on days 1 and 8</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride (normal saline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or nonpregnant female, ages 18 to 70 years inclusive, at Screening Visit.

          2. Biopsy-confirmed CD (intestinal histology showing villous atrophy).

          3. Positive for human leukocyte antigen (HLA)-DQ2 or HLA-DQ2/DQ8 - results will be
             obtained at Screening if unknown or results are not available.

          4. Self-reported to be on a GFD for at least 6 months prior to Screening and agree to
             continue GFD throughout study, with the exception of the oral gluten challenge.

          5. Normal or negative celiac serology, at screening, defined as:

               1. Measurable total serum immunoglobulin A (IgA) AND

               2. Negative or weak positive tissue transglutaminase (tTG) IgA titer OR

               3. If IgA deficient, defined by a serum IgA level of &lt; 3 mg/dL, negative or weak
                  positive DGP- IgG titer.

          6. Vh:Cd ≥ 1.5 on screening biopsy.

        Key Exclusion Criteria:

          1. Positive for only HLA-DQ8.

          2. History of clinically confirmed immunoglobulin E (IgE)-mediated reaction and/or
             anaphylaxis to wheat (i.e., &quot;wheat allergy&quot;), barley or rye.

          3. Uncontrolled CD and/or active signs/symptoms of CD, in the opinion of the
             investigator.

          4. Untreated or active gastrointestinal disease such as peptic ulcer disease, esophagitis
             (Los Angeles Classification ≥ Grade C), irritable bowel syndrome, inflammatory bowel
             disease, or microscopic colitis.

          5. Immunocompromised individuals, including those receiving immunosuppressive doses of
             corticosteroids (more than 20 mg of prednisone given daily or on alternative days for
             2 weeks or more within 6 months prior Dose 1, any dose of corticosteroids within 30
             days of Day 1, or high dose inhaled corticosteroids [&gt; 960 µg/day of beclomethasone
             dipropionate or equivalent]) or other immunosuppressive agents.

          6. Presence or history of celiac-associated thyroid disease or Type 1 diabetes,
             regardless of current treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis Gastroenterology Research Foundation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 22, 2020</submitted>
    <returned>July 15, 2020</returned>
    <submitted>July 27, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

